1. Signaling Pathways
  2. Antibody-drug Conjugate/ADC Related
  3. Drug-Linker Conjugates for ADC

Drug-Linker Conjugates for ADC

Drug-Linker Conjugates for Antibody Drug Conjugates (ADC) comprise of an active cytotoxic drug and an appropriate linker. The Drug-Linker Conjugates can expand the utility of monoclonal antibody (mAbs) and improve their potency and effectiveness. The site-specific conjugations of Drug-Linker to an antibody may involve genetic engineering of the mAb to introduce discrete, available cysteines or non-natural amino acids with an orthogonally-reactive functional group handle. These site-specific approaches not only increase the homogeneity of ADCs but also enable novel bio-orthogonal chemistries that utilize reactive moieties other than thiol or amine. The cytotoxic drug, monomethyl auristatin E (MMAE), is conjugated to the three trastuzumab variants using a protease cleavable linker and shows in vivo therapeutic efficacy.

Drug-Linker Conjugates for ADC Isoform Specific Products:

  • Auristatin

  • Camptothecins

  • Daunorubicins/Doxorubicins

  • Duocarmycins

  • Maytansinoids

  • Pyrrolobenzodiazepines

  • Traditional Cytotoxic Agents

Drug-Linker Conjugates for ADC Related Products (80):

Cat. No. Product Name Effect Purity
  • HY-15575
    VcMMAE 99.89%
    VcMMAE (mc-vc-PAB-MMAE) is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).
  • HY-101070
    SMCC-DM1 99.02%
    SMCC-DM1 (DM1-SMCC) is a drug-linker conjugate composed of a potent microtubule-disrupting agent DM1 and a linker SMCC to make antibody drug conjugate.
  • HY-15578
    McMMAF 99.94%
    McMMAF is a protective group-conjugated MMAF. MMAF is a potent tubulin polymerization inhibitor.
  • HY-111012
    DBCO-(PEG)3-VC-PAB-MMAE Chemical 98.07%
    DBCO-(PEG)3-VC-PAB-MMAE is made by MMAE conjugated to DBCO-(PEG)3-vc-PAB linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate.
  • HY-13631E
    Deruxtecan 99.43%
    Deruxtecan, a toxin (DNA Topoisomerase I inhibitor) and linker moiety of DS-8201, is a drug-linker conjugate for antibody-drug conjugate (ADC) extracted from patent WO2017002776A1, compound 1.
  • HY-128870
    Mal-PEG2-VCP-Eribulin
    Mal-PEG2-VCP-Eribulin consists the ADCs linker (Mal-PEG2-VCP) and Eribulin. Eribulin is a mechanistically unique microtubule inhibitor for cancer. Mal-PEG2-VCP-Eribulin is an Eribulin-based drug for antibody conjugates.
  • HY-128943
    MAC glucuronide phenol-linked SN-38
    MAC glucuronide phenol-linked SN-38 is a pH-susceptible lactone MAC glucuronide phenol-linked SN-38 (DNA topoisomerase I inhibitor) drug linker. MAC glucuronide phenol-linked SN-38 is cytotoxic across L540cy cells and Ramos cells with IC50 values of 113 and 67 ng/mL, respectively.
  • HY-128711
    MAL-di-EG-Val-Cit-PAB-MMAF 98.56%
    MAL-di-EG-Val-Cit-PAB-MMAF consists the ADCs linker (MAL-di-EG-Val-Cit-PAB) and potent tubulin polymerization blocker (MMAF, Monomethyl auristatin F).
  • HY-100566
    SuO-Val-Cit-PAB-MMAE
    SuO-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the peptide SuO-Val-Cit-PAB.
  • HY-100374
    Val-Cit-PAB-MMAE 99.83%
    Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the peptide Val-Cit-PAB.
  • HY-100567
    MAL-di-EG-Val-Cit-PAB-MMAE 98.92%
    MAL-di-EG-Val-Cit-PAB-MMAE consists the ADCs linker (MAL-di-EG-Val-Cit-PAB) and potent tubulin inhibitor (MMAE).
  • HY-15741
    Mc-MMAE
    Mc-MMAE is a protective group (maleimidocaproyl)-conjugated monomethyl auristatin E (MMAE), which is a potent tubulin inhibitor. Mc-MMAE is a drug-linker conjugate for ADC.
  • HY-101982
    Lys-SMCC-DM1
    Lys-SMCC-DM1 is the active metabolite of DM1. DM1 is a tubulin inhibitor.
  • HY-100874
    N3-PEG3-vc-PAB-MMAE 99.18%
    N3-PEG3-vc-PAB-MMAE is a synthesized drug-linker conjugate for ADC that incorporates the MMAE (a tubulin inhibitor ) and 3-unit PEG linker. N3-PEG3-vc-PAB-MMAE shows potent antitumor activity.
  • HY-12460
    SPDB-DM4
    SPDB-DM4 is a drug-linker conjugate for ADC by using the maytansinebased payload (DM4, a tubulin inhibitor) via a SPDB linker, exhibiting potent anti-tumor activity.
  • HY-19812
    Acetylene-linker-Val-Cit-PABC-MMAE
    Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) consists the ADCs linker (Acetylene-linker-Val-Cit-PABC) and potent tubulin inhibitor (MMAE). Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) is a drug-linker conjugate for ADC.
  • HY-19811
    Fmoc-Val-Cit-PAB-MMAE
    Fmoc-Val-Cit-PAB-MMAE consists the ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). Fmoc-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC.
  • HY-101141
    sulfo-SPDB-DM4
    sulfo-SPDB-DM4 is a drug-linker conjugate for ADC by using the maytansinebased payload (DM4, an antitubulin agent) via the sulfo-SPDB linker.
  • HY-15740
    Mc-MMAD 98.50%
    Mc-MMAD is a protective group (maleimidocaproyl)-conjugated MMAD. MMAD is a potent tubulin inhibitor. Mc-MMAD is a drug-linker conjugate for ADC.
  • HY-16261A
    MC-DOXHZN
    MC-DOXHZN is an albumin-binding prodrug of Doxorubicin (DNA topoisomerase II inhibitor), with acid-sensitive properties.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.